A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

McDonald, AC and Jenkins, FJ and Bunker, CH and Wilson, JW and Patrick, AL and Weissfeld, JL (2011) A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. Infectious Agents and Cancer, 6 (1).

Preview	PDF Published Version Available under License : See the attached license file. Download (456kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings. Methods. In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later. Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69). Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer. © 2011 McDonald et al; licensee BioMed Central Ltd.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID McDonald, AC Jenkins, FJ fjenkins@pitt.edu FJENKINS Bunker, CH BUNKERC@pitt.edu BUNKERC Wilson, JW jww@pitt.edu JWW Patrick, AL Weissfeld, JL
Centers:	Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date:	8 December 2011
Date Type:	Publication
Journal or Publication Title:	Infectious Agents and Cancer
Volume:	6
Number:	1
DOI or Unique Handle:	10.1186/1750-9378-6-25
Schools and Programs:	School of Public Health > Biostatistics School of Public Health > Epidemiology School of Medicine > Pathology
Refereed:	Yes
Date Deposited:	01 Nov 2016 16:47
Last Modified:	30 Oct 2018 13:56
URI:	http://d-scholarship.pitt.edu/id/eprint/29989

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item